From: financialbuzz.com DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that its Phase 2 study testing VAL-083 in patients with newly diagnosed glioblastoma multiforme (GBM) has achieved its halfway enrollment point. This trial, targeted to enroll up to thirty patients, is a single-arm, open-label study …
Immunomedics Announces Publication of Triple-Negative Breast Cancer Data With Sacituzumab Govitecan in the New England Journal of Medicine
Source: Immunomedics From: globenewswire.com Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that updated data from the Phase 2 study of sacituzumab govitecan in patients with metastatic triple-negative breast cancer (mTNBC) were published on NEJM.org as part of the February 21 print issue of the New England …
John Theurer Cancer Center Leading Enrollment for Global Phase 2 WIZARD Study Evaluating DSP-7888 in Patients with Recurrent Glioblastoma
Source: John Theurer Cancer Center From: prnewswire.com John Theurer Cancer Center at Hackensack Meridian Health Hackensack University Medical Center announced today that it is leading enrollment worldwide for WIZARD 201G, a global Phase 2 study in glioblastoma (GBM). The trial, sponsored by Boston Biomedical, is evaluating DSP-7888, an investigational cancer vaccine, in combination with bevacizumab for recurrent disease. Glioblastoma is the …
Sermonix Reports FDA Acceptance of IND Application; Will Begin Phase 2 Trial of Lasofoxifene
From: streetinsider.com Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced that the U.S. Food and Drug Administration (FDA) accepted the company’s Investigational New Drug (IND) application, indicating that Sermonix may proceed directly to a Phase 2 clinical study in the personalized medicine arena involving its lead investigational drug, …
Inovio Announces Initiation of “MD Anderson’s HPV-Related Cancers Moon Shot” Phase 2 Trial in New HPV Indications
Source: Inovio Pharmaceuticals, Inc. From: globenewswire.com Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today the dosing of the first patient in a Phase 2 combination trial to evaluate MedImmune’s MEDI0457 (formerly called INO-3112 which MedImmune in-licensed from Inovio) in combination with durvalumab targeting a broad array of cancers associated with the human papilloma virus (HPV). This open-label trial funded by MedImmune, the …